PRKN and Parkinson disease: In conclusion, the main finding of our current study is that the AMPK activation is physiologically upregulated in the mammalian ventral midbrain and selectively reduced in the same region in the absence of Parkin or PINK1, the deficiency of which may contribute to SNpc DA neurodegeneration in Parkin/PINK1-related PD cases.